Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR-1222
- Development stage
- Phase 1
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous Injection
01
Overview
SHR-1222 is a novel humanized monoclonal antibody targeting sclerostin (SOST), a protein that inhibits bone formation. By inhibiting sclerostin, SHR-1222 promotes bone formation and decreases bone resorption, making it a promising therapeutic candidate for osteoporosis treatment. It has been shown in clinical studies to increase bone mineral density (BMD) notably at the lumbar spine and modulate biomarkers related to bone metabolism such as increasing N-terminal propeptide of type 1 procollagen, osteocalcin, and bone-specific alkaline phosphatase while decreasing β-C-telopeptide. The drug is administered subcutaneously and has demonstrated dose-dependent pharmacokinetics with good tolerability in phase I and II clinical trials conducted primarily in China. Developed by Jiangsu Hengrui Medicine Co., SHR-1222 is currently in phase II development for osteoporosis.
- Other names
- SHR 1222SHR1222SHR-1222Resugosbart
02
Targets
SOST (Sclerostin)
Beyond the preview
Go deeper on SHR-1222.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR-1222.